sertanty.com

What It Is

Eidogen-Sertanty positions itself as a provider of AI-driven software, knowledgebases, and health innovation tools for drug discovery, with a focus on pharmaceutical R&D use cases. The collected text highlights three core products: Kinase Knowledgebase (KKB), Oncology Knowledgebase (OKB), and Target Informatics Platform (TIP™). Based on publicly available information, it appears to be more of a “vertical data asset for drug discovery + target informatics platform” than a general-purpose AI assistant.

Core Capabilities and Data Foundation

KKB focuses on the kinase field. Its Q1 2026 version includes 10,310 journal articles and patents, 3,086,886 bioactivity data points, 449,553 unique kinase molecules with assay data, and 579 unique kinase targets with assay data. OKB focuses on oncology. Its Q2 2023 version includes 146,206 bioactivity data points, 66,198 molecules, 1,158 oncology targets, and 137 disease models. TIP provides more than 200K high-resolution protein structures, about 1.2M annotated co-complex sites, and around 875K predicted sites, covering major drug target families. Although the website describes the platform as AI-powered, it does not disclose specific models, algorithms, or validation metrics.

Pricing, Integration, and Privacy

The collected content does not provide details on pricing model, free trials, payment methods, API access, enterprise integration, deployment options, or data privacy policy. As a result, it is not possible to assess procurement barriers, whether it can integrate with internal R&D systems, or whether it meets pharmaceutical compliance requirements. For enterprise evaluation, buyers should further confirm licensing scope, data update frequency, export permissions, and security terms with the vendor.

Pros, Cons, and Best-Fit Users

Its strengths are concentrated domain data and what appears to be a relatively high level of structure, making it especially suitable for research related to kinases, oncology targets, protein structures, and binding sites. The main limitation is that the public pages read more like a product catalog, with limited transparency around AI capabilities, user interface experience, output quality evaluation, and commercial terms. It is best suited for pharmaceutical companies, CROs, computational chemistry teams, structural biology groups, and target discovery teams as a specialized database or R&D decision-support tool.

Access from China and Alternatives

Mainland China access, network connectivity, payment options, and Chinese-language support are not described in the text, so they should be considered unknown. If access or procurement is restricted, alternatives to compare include Schrödinger, Cresset, Certara, BenchSci, CAS SciFinder, Elsevier Reaxys, and the AlphaFold-related structural biology tool ecosystem.